Project Grant R44AI152726

The National Heart, Lung, and Blood Institute (NHLBI) awarded $448,250 to The Research Foundation for the State University of New York (operating as Upstate Medical Center) under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant that commenced May 15, 2026 and is scheduled for completion April 30, 2028. The award supports the development and preclinical evaluation of a lung-targeting immunomodulatory messenger RNA (mRNA) therapy designed to treat Acute Respiratory...

This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...

Federal Grant Award Summary Inhalon Biopharma, Inc. received a Project Grant award of $1,013,003 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2028. The award supports investigator-initiated research and development activities focused on advancing IN-005, an inhaled monoclonal antibody (MAb) therapeutic candidate designed to treat seasonal influenza A virus...

Federal Project Grant Award Summary Inhalon Biopharma, Inc. received a $1,013,468 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 1, 2025, with completion targeted for July 31, 2028. The company is developing IN-003PI, a passive immunization therapeutic comprised of a pair of neutralizing monoclonal antibodies (mAbs) against human metapneumovirus (MPV) fusion proteins....

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...

Federal Project Grant Award Summary Award Details: New York University School of Medicine received a $3.17M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2029. This award supports the development and optimization of the L7AE protein as a broad-spectrum antiviral therapeutic targeting orthomyxoviridae family infections, including influenza...

Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital a $661,313 Project Grant (CFDA 93.855: Allergy and Infectious Diseases Research) effective February 6, 2026, through January 31, 2031, to develop a universal influenza vaccine targeting all influenza A viruses (IAV). Under the direction of Principal Investigator Dr. Daniel Lingwood and Co-Investigator Dr. Batista at the Ragon Institute of MGH, MIT and Harvard, the...

This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Cooperative Agreement valued at $1.67 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase 1 clinical study of a novel messenger ribonucleic acid (mRNA)-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The research, initiated September 25, 2025, and scheduled for completion by July...

Federal Project Grant Award Summary Orpro Therapeutics Inc. received a $508,988 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 24, 2025, with completion targeted for August 31, 2027. The project centers on the development and evaluation of ORP100S, a pre-reduced, monothiol variant of human thioredoxin-1 (TRX) engineered for pharmaceutical application. The...